by Melanie Lödige, Matthew D. Lewis, Eleonora S. Paulsen et al.
International Journal of Medical Microbiology, 5 August 2013
The authors present a new class of hybrid molecules consisting of the established antiplasmodial drugs primaquine and chloroquine. No drug is known to date that acts comparably against all stages of Plasmodium in its lifecycle. It is hoped that the novel design of such compounds will outwit the pathogen in the spread of drug resistance. Based on the optimized synthetic pathway, the compound is accessible in a smooth and versatile way and open for potential further molecular modification.